Iconic Labs
This article was originally published in The Rose Sheet
Executive Summary
New premium health and beauty firm launches with two brands, hair-care brand Ookisa and soon-to-come anti-aging skin-care brand Kumaara, according to the March 3 release. The Los Angeles, Calif.-based company champions skin- and hair-care formulations "that combine the most sought-after and time-proven natural and organic beauty ingredients from around the world with the latest in scientific innovation." Ookisa takes a "system approach" to hair health with a volumizing and thickening regime consisting of Fortifying Shampoo, Replenishing Conditioner, Instant Volumizing Souffle - just under $30 apiece - and Nighttime Follicle Renewing Serum, priced at $62.95. Kumaara products contain a blend of antioxidant fruits, a "patented growth factor" and "advanced wrinkle-fighting ingredients." Items will be sold under a direct-to-consumer model supported by online marketing and "aggressive" public relations efforts, firm says. "We feel that this is a perfect approach because we can develop premium products in an unfettered, no-holds-barred environment - and offer them to consumers at prices unattainable in traditional retail settings," says Senior Director of Marketing Casi Morris
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.